CVS Health Corporation (BCBA:CVS)
Argentina · Delayed Price · Currency is ARS | Market Cap | 187.54T +53.6% |
| Revenue (ttm) | 611.33T +7.4% |
| Net Income | 7.24T +7.9% |
| EPS | 5,654.08 +6.3% |
| Shares Out | n/a |
| PE Ratio | 25.89 |
| Forward PE | 11.81 |
| Dividend | 161.68 (1.59%) |
| Ex-Dividend Date | Jul 23, 2026 |
| Volume | 2,385 |
| Open | 10,310 |
| Previous Close | 10,330 |
| Day's Range | 10,100 - 10,400 |
| 52-Week Range | 6,550 - 12,000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About CVS Health
CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans; medical management capabilities; Medicare Advantage and Medicare Supplement plans; prescription drug plans (PDPs); and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care prov... [Read more]
Financial Performance
In 2025, CVS Health's revenue was $399.83 billion, an increase of 7.87% compared to the previous year's $370.66 billion. Earnings were $1.77 billion, a decrease of -61.68%.
Financial numbers in USD Financial StatementsNews
These stocks in the red-hot healthcare sector have gotten too crowded to own
New recommendations include making an options bet that the stocks of GE HealthCare and Medtronic will fall, because there were too many bets already made that the stock would rise.
Updated COVID-19 vaccines available at CVS Pharmacy and MinuteClinic across the U.S.
Appointments can be scheduled through the CVS Health app or CVS.com and walk-ins are accepted WOONSOCKET, R.I., Sept. 3, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that updated 2026-...
CVS Health price target lowered to $118 from $126 at UBS
UBS lowered the firm’s price target on CVS Health (CVS) to $118 from $126 and keeps a Buy rating on the shares.
Did CVS Health Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
CVS Health remains top large cap pick in healthcare services at Jefferies
Jefferies highlights CVS Health (CVS) as one of the analyst’s top picks and its top large cap pick in healthcare services, citing a belief that management commentary points to $8.44…
CVS Health: 2026-2027 flu vaccines now available at CVS Pharmacy, MinuteClinic
CVS Health (CVS) announced that updated 2026-2027 flu vaccines are now available at CVS Pharmacy and MinuteClinic locations nationwide. According to the Centers for Disease Control and Prevention, ann...
CVS Pharmacy® and MinuteClinic® now offering updated flu vaccines nationwide
CVS Health survey finds more than 60 percent of consumers say they are likely to get a flu shot this season. Expanded testing and treatment services help make CVS Pharmacy a convenient destination for...
As Health Insurers Gain Handle On Costs, Stocks Are Soaring Again
Following a parade of health insurance company earnings reports this summer, stocks are rising and costs appear to be under control for now.
CVS Health price target raised to $114 from $104 at Argus
Argus raised the firm’s price target on CVS Health (CVS) to $114 from $104 and keeps a Buy rating on the shares. CVS remains well positioned to capitalize on favorable…
CVS Health appoints Teresa Heitsenrether to board, Larry Robbins departs
CVS Health (CVS) announced the appointment of Teresa Heitsenrether to its Board of Directors and departure of Larry Robbins from its Board. Heitsenrether joins the CVS Health Board with nearly…
CVS Health Announces Board Changes
Teresa Heitsenrether to join the Board, bringing more than forty years of operating experience across data, analytics and technology at one of the world's largest financial institutions Larry Robbins ...
CVS Health price target raised to $118 from $111 at JPMorgan
JPMorgan raised the firm’s price target on CVS Health (CVS) to $118 from $111 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published first…
New study from CVS Caremark and Employee Benefit News shows how employers rely on their pharmacy benefit manager to create sustainable pharmacy solutions
Key opportunities include: managing GLP-1s, encouraging biosimilar substitution and employing technology to simplify and personalize the member experience WOONSOCKET, R.I., Aug. 12, 2026 /PRNewswire/ ...
Broad Market Momentum & Defensive Pivots: This Week's Top ETF Flows
The ETF market saw a massive surge into core index heavyweights this past week, as investors poured billions into broad U.S. equities and mega-cap tech leadership. However, this aggressive accumulatio...
Medicare Made Weight-Loss Drugs $50 A Month—Now Amazon, CVS And Walmart Race To Fill Prescriptions
More than 66 million. That's how many people in the U.S. get their health coverage from Medicare, according to the insurance program.
CVS Health price target raised to $107 from $94 at Baird
Baird analyst Michael Ha raised the firm’s price target on CVS Health (CVS) to $107 from $94 and keeps an Outperform rating on the shares.
CVS Health price target lowered to $125 from $130 at Evercore ISI
Evercore ISI lowered the firm’s price target on CVS Health (CVS) to $125 from $130 and keeps an Outperform rating on the shares.
CVS Health price target raised to $126 from $122 at UBS
UBS raised the firm’s price target on CVS Health (CVS) to $126 from $122 and keeps a Buy rating on the shares. CVS delivered a better-than-expected quarter with improving HCB…
CVS Health price target raised to $108 from $106 at Barclays
Barclays raised the firm’s price target on CVS Health (CVS) to $108 from $106 and keeps an Overweight rating on the shares post the Q2 report. The company called out…
CVS Stock Drops 6% as Early 2027 Warnings Shadow Strong $2.9 Billion Profit Beat
CVS Health shares ($CVS) fell about 6% on Wednesday despite net income nearly tripling to $2.98 billion, or $2.31 per share, for the second quarter. Investors focused on future customer…
CVS Health says ‘encouraged by the momentum we’re seeing’
Says continuing to implement technology enhancements. Says embedding AI into the company’s processes. Says maintaining “disciplined approach” to costs, price actions. Comments taken from Q2 earnings c...
CVS Health seeing ‘pockets of favorability’ in Medicare business
Says leverage ratio was 3.5x at end of Q2 and expects further improvement by year end. Says will continue to evaluate capital deployment strategies. Expects 2H EPS “weighted towards Q3.”…
CVS Health says FY27 EPS of at least $8.44 ‘seems reasonable’
FY27 EPS consensus $8.43.
CVS Health Earnings Call Transcript: Q2 2026
Q2 2026 saw broad-based revenue and earnings growth, with adjusted EPS up 40% and all segments outperforming. Full-year guidance was raised for EPS and cash flow, driven by strong pharmacy, health services, and benefits results, despite ongoing 340B and reimbursement headwinds.
CVS Health Quarterly report: Q2 2026
CVS Health has published its Q2 2026 quarterly earnings report on August 5, 2026.